Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Sep 18:17:2861-2873.
doi: 10.2147/DDDT.S427416. eCollection 2023.

Faricimab: Transforming the Future of Macular Diseases Treatment - A Comprehensive Review of Clinical Studies

Georgios D Panos  1   2 , Arun Lakshmanan  1 , Panagiotis Dadoukis  3 , Matteo Ripa  4 , Lorenzo Motta  4 , Winfried M Amoaku  1   2
Affiliations
Review

Faricimab: Transforming the Future of Macular Diseases Treatment - A Comprehensive Review of Clinical Studies

Georgios D Panos et al. Drug Des Devel Ther. .

Abstract

Degenerative eye conditions such as age-related macular degeneration (AMD), diabetic retinopathy, and retinal vein occlusion are major contributors to significant vision loss in developed nations. The primary therapeutic approach for managing complications linked to these diseases involves the intravitreal delivery of anti-vascular endothelial growth factor (VEGF) treatments. Faricimab is a novel, humanised, bispecific antibody that simultaneously binds all VEGF-A isoforms and Angiopoietin-2, which has been approved by regulatory agencies, such as the US Food and Drug Administration (FDA), the UK Medicines and Healthcare products Regulatory Agency (MHRA) and the European Medicines Agency (EMA), for the treatment of neovascular AMD and diabetic macular oedema (DMO). Intravitreal faricimab holds the promise of reducing the treatment burden for patients with these conditions by achieving comparable or superior therapeutic outcomes with fewer clinic visits. The scope of faricimab's application includes addressing complex macular conditions such as DMO. This review intends to elucidate the distinctive pharmacological characteristics of faricimab and provide an overview of the key clinical trials and real-world studies that assess its effectiveness and safety in treating degenerative macular diseases.

Keywords: age-related macular degeneration; anti-VEGF; degenerative macular disorders; diabetic macular oedema; diabetic retinopathy; efficacy; faricimab; intravitreal treatment; retinal vein occlusion; safety.

PubMed Disclaimer

Conflict of interest statement

Winfried M Amoaku has provided consultancy services to Alcon, Alimera, Allergan (AbbVie), Bayer, Novartis and Roche. The other authors report no conflicts of interest in this work.

Figures

Figure 1
Figure 1
Mechanism of action of Faricimab.
See this image and copyright information in PMC

References

    1. Wong WL, Su X, Li X, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014;2(2):e106–116. doi:10.1016/S2214-109X(13)70145-1 - DOI - PubMed
    1. Bourne RR, Stevens GA, White RA, et al. Causes of vision loss worldwide, 1990–2010: a systematic analysis. Lancet Glob Health. 2013;1(6):e339–349. doi:10.1016/S2214-109X(13)70113-X - DOI - PubMed
    1. Mitchell P, Liew G, Gopinath B, Wong TY. Age-related macular degeneration. Lancet. 2018;392(10153):1147–1159. doi:10.1016/S0140-6736(18)31550-2 - DOI - PubMed
    1. Yau JW, Rogers SL, Kawasaki R, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012;35(3):556–564. doi:10.2337/dc11-1909 - DOI - PMC - PubMed
    1. Rogers S, McIntosh RL, Cheung N, et al. The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology. 2010;117(2):313–319 e311. doi:10.1016/j.ophtha.2009.07.017 - DOI - PMC - PubMed

MeSH terms